Who could benefit the most from long-acting antiretroviral therapy? perspectives of HIV care providers and people with HIV in Florida.
Saved in:
| Title: | Who could benefit the most from long-acting antiretroviral therapy? perspectives of HIV care providers and people with HIV in Florida. |
|---|---|
| Authors: | Fisk-Hoffman, Rebecca J., Gracy, Abigail, Ranger, Sashaun S., Manavalan, Preeti, Widmeyer, Maya, Cook, Robert L., Canidate, Shantrel S. |
| Source: | AIDS Care. Jul2025, Vol. 37 Issue 7, p1150-1159. 10p. |
| Subjects: | Rilpivirine, Combination drug therapy, Antiretroviral agents, Medical personnel, Qualitative research, Patient safety, Research funding, Interviewing, Statistical sampling, Long-term health care, HIV infections, Descriptive statistics, Judgment sampling, Psychology of HIV-positive persons, Longitudinal method, Race, Attitudes of medical personnel, Research methodology, Cisgender people, Comparative studies, Housing stability, Patients' attitudes, Psychosocial factors |
| Geographic Terms: | Florida |
| Abstract: | Injectable cabotegravir/rilpivirine (CAB/RPV) is now available, and other long-acting antiretroviral therapy (ART) regimens are in development. The present study describes the factors that HIV care providers and people with HIV (PWH) in Florida (a high HIV incidence and prevalence setting) consider when assessing populations of PWH who could benefit from long-acting ART. We conducted semi-structured qualitative interviews with 11 providers (27% non-Hispanic Black, 27% Hispanic, 73% cis women) and 16 PWH (31% non-Hispanic Black, 19% Hispanic, 50% cis men, 69% aged 50+) from five sites in Florida. Participants were asked about the groups of PWH who they thought could benefit the most from long-acting ART. Responses were analyzed using a reflexive thematic approach. Seven populations of PWH who could benefit from long-acting ART were identified: 1) younger PWH, 2) PWH with co-occurring conditions, 3) PWH who use substances, 4) PWH experiencing housing instability, 5) PWH with frequent travel, 6) PWH experiencing stigma, and 7) PWH who reliably take medication and engage in care. Many groups who may be excluded from injectable CAB/RPV based on the current guidelines were seen as potentially benefiting from such an option. [ABSTRACT FROM AUTHOR] |
| Copyright of AIDS Care is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Injectable cabotegravir/rilpivirine (CAB/RPV) is now available, and other long-acting antiretroviral therapy (ART) regimens are in development. The present study describes the factors that HIV care providers and people with HIV (PWH) in Florida (a high HIV incidence and prevalence setting) consider when assessing populations of PWH who could benefit from long-acting ART. We conducted semi-structured qualitative interviews with 11 providers (27% non-Hispanic Black, 27% Hispanic, 73% cis women) and 16 PWH (31% non-Hispanic Black, 19% Hispanic, 50% cis men, 69% aged 50+) from five sites in Florida. Participants were asked about the groups of PWH who they thought could benefit the most from long-acting ART. Responses were analyzed using a reflexive thematic approach. Seven populations of PWH who could benefit from long-acting ART were identified: 1) younger PWH, 2) PWH with co-occurring conditions, 3) PWH who use substances, 4) PWH experiencing housing instability, 5) PWH with frequent travel, 6) PWH experiencing stigma, and 7) PWH who reliably take medication and engage in care. Many groups who may be excluded from injectable CAB/RPV based on the current guidelines were seen as potentially benefiting from such an option. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 09540121 |
| DOI: | 10.1080/09540121.2025.2510915 |
